For health system and digital health leaders, enterprise value is often assessed through familiar financial lenses, such as revenue growth, EBITDA margins, and scale potential. These metrics remain important. However, in digital health, they rarely explain why value persists, where risk accumulates, or how short-term performance translates into long-term enterprise value.
This disconnect exists because the attributes that ultimately determine durability, transferability, and scalability in digital health are largely intangible rather than financial.
The gap between financial performance and enterprise value is not just theoretical; it is where board-level surprises tend to emerge:
From a CFO standpoint, the distinction between performance and value is therefore critical. Performance metrics explain what has occurred. Value reflects expectations about what a market participant believes will continue to occur after accounting for durability, transferability, and scalability. In digital health, those expectations are shaped less by reported financial results and more by assets that are difficult to observe, slow to replace, and deeply embedded in the operating model. Collectively, these elements form what can be thought of as a company’s intangible stack.
Digital health businesses operate under constraints that fundamentally reshape how value is created and sustained. Unlike consumer technology companies, scaling in digital health is not driven solely by product adoption or engineering velocity. Instead, performance depends on a tightly linked set of operational and regulatory prerequisites. Digital health companies must demonstrate:
These factors determine whether a solution can be deployed, how quickly it can scale, and how durable its economics will be over time. Importantly, they are rarely visible in traditional financial statements. As a result, two digital health companies with similar revenue profiles and margins can exhibit materially different enterprise values depending on the quality, maturity, and sustainability of the intangible capabilities supporting those results.
Every digital health company operates with an intangible stack: the unique combination of data assets, workflows, regulatory approvals, compliance infrastructure, and partner relationships that underpin its competitive positioning. Some components of this stack generate revenue directly. Others function as the prerequisites that allow the business to operate, contract, and grow without disruption.
From a CFO perspective, understanding this stack is less about labeling assets and more about answering three questions:
Financial metrics rarely answer these questions on their own. The intangible stack often provides the missing clarity.
One of the most frequent sources of misalignment between internal expectations and external outcomes is the misclassification of value. In practice, value is often attributed to assets that have not yet become transferable or repeatable. Common examples include:
For CFOs, the issue is not whether these elements matter (they do). Rather, it’s whether they have matured into assets that a market participant can rely upon independent of continued execution by the same people under the same conditions. Failing to make that distinction can lead to overstated expectations of enterprise value.
The dominance of intangible assets in digital health has several governance implications. First, value deterioration often begins before it appears in earnings. Compliance gaps, fragile referral relationships, workforce concentration, and/or weak payor alignment may not immediately affect margins, but they can materially affect risk‑adjusted value.
Secondly, capital allocation decisions increasingly shape intangible value. Investments in compliance infrastructure, workflow standardization, clinical validation, and data governance may not yield immediate financial returns, but they often determine whether future growth is durable and transferable.
Finally, valuation outcomes should not be viewed as end‑stage exercises tied solely to transactions. For boards and CFOs, valuation thinking is most effective when used proactively. This includes stress‑testing strategies, assessing risk, and aligning expectations well before external scrutiny arises.
In digital health, enterprise value is rarely explained by financial results alone. It is shaped by the quality and maturity of the assets that govern how risk manifests and how performance can be sustained over time. Understanding how value is created is foundational. In practice, however, many valuation outcomes fail not because leaders misunderstand value creation, but because risk, transferability, and defensibility are not handled rigorously once scrutiny begins.
For more information on this topic, please contact a member of our team.
For years, S corporations have been the entity of choice for many closely held businesses. The structure offers pass-through taxation, generally avoids a second layer of tax and provides operational flexibility. But as founders of S corporations begin planning for a future sale, many discover one of the most powerful tax incentives available to business…
For many startup companies, innovation comes long before profitability. While early-stage businesses often invest heavily in software development, product design, engineering or process improvement, they may have little or no federal income tax liability against which to utilize valuable tax credits. Recognizing this challenge, Congress created a special provision that allows startup companies to monetize…
In digital health, valuation is often treated as a technical requirement-something performed for compliance, reporting, or transaction support. For CFOs, however, valuation is most valuable when it functions as a recurring operating discipline: a structured way to understand risk, test assumptions, and inform decisions under uncertainty. Used correctly, valuation does not simply answer questions of…
